Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 3Gastrointestinal 2Breast 2Sarcoma 1Other solid neoplasm 1Head & Neck 1Gynecologic 1Genitourinary 1Dermatologic 1

Conditions

Triple Negative Breast Neoplasms 16Carcinoma, Non-Small-Cell Lung 7Pancreatic Neoplasms 6Melanoma 6Breast Neoplasms 6Carcinoma, Renal Cell 5Lung Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Head and Neck Neoplasms 3Colorectal Neoplasms 3Uterine Cervical Neoplasms 2Stomach Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma 2Ovarian Neoplasms 2Neoplasms 2Liver Neoplasms 2Esophageal Squamous Cell Carcinoma 2Endometrial Neoplasms 2Colonic Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Ovarian Epithelial 2Carcinoma, Hepatocellular 2Anus Neoplasms 2Adenocarcinoma of Lung 2Adenocarcinoma Of Esophagus 2Adenocarcinoma 2Uveal Melanoma 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1

Interventions

pembrolizumab 3spartalizumab 2sargramostim 2trametinib 1tislelizumab 1nazartinib 1fludarabine phosphate 1enzalutamide 1canakinumab 1bemarituzumab 1Specimen Handling 1Midazolam 1Magnetic Resonance Spectroscopy 1Letrozole 1Interleukin-13 1IFL protocol 1Fulvestrant 1Fluorodeoxyglucose F18 1Cyclophosphamide 1Cetuximab 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Adenocarcinoma of Lung × spartalizumab × Breast × Clear all
NCT04802876 2025-03-21

ACROPOLI

SOLTI Breast Cancer Research Group

Phase 2 Active not recruiting
184 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmSarcomaThoracic

Adenocarcinoma Of Esophagus, Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Uveal Melanoma, Anus Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Neoplasms, Unknown Primary, Sarcoma, Thyroid Neoplasms, Cholangiocarcinoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT02900664 2022-03-29

A Study of PDR001 in Combination With CJM112, EGF816, IlarisĀ® (Canakinumab) or MekinistĀ® (Trametinib)

Novartis

Phase 1 Completed
283 enrolled
BreastGastrointestinalThoracic

Adenocarcinoma of Lung, Adenocarcinoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Intestinal Neoplasms, Lung Neoplasms, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Ductal, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚔